Volume 71, Issue 5_suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
Preview this article:
Zoom in


| /docserver/preview/fulltext/14761645/71/5_suppl/0700012-1.gif

There is no abstract available for this article.
Use the preview function to the left.


Article metrics loading...

Loading full text...

Full text loading...



  1. Seim A, Dreyer G, Addis D, 1999. Controlling morbidity and interrupting transmission: twin pillars of lymphatic filariasis elimination. Rev Soc Bras Med Trop 32: 325–328.
  2. Fan PC, Peng HW, Chen CC, 1995. Follow-up investigations on clinical manifestations after filariasis eradication by diethylcarbamazine medicated common salt on Kihmen (Quemoy) Island, Republic of China. Am J Trop Med Hyg 98: 461–464.
  3. Suma TK, Shenoy RK, Kumaraswami V, 2002. Efficacy and sustainability of a footcare programme in preventing acute attacks of adenolymphangitis in Brugian filariasis. Trop Med Int Health 7: 763–766.
  4. Shenoy RK, Suma TK, Rajan K, Kumaraswami V, 1998. Prevention of acute adenolymphangitis in Brugian filariasis: comparison of the efficacy of ivermectin and diethylcarbamazine, each combined with local treatment of the affected limb. Ann Trop Med Parasitol 92: 587–594.
  5. McPherson T, 2003. Impact on the quality of life of lymphoedema patients following introduction of a hygiene and skin care regimen in a Guyanese community endemic for lymphatic filariasis: a preliminary clinical intervention study. Filaria J 2: 1.
  6. Coreil J, Mayard G, Addis D, 2002. Benefits of support groups in the management of filariasis. TDR Final Report Series, No. 56, Lymphatic Filariasis. Geneva: World Health Organization.
  7. Dreyer G, Addiss D, Noroes J, 2002. Basic Lympheodema Management: Treatment and Prevention of Problems Associated with Lymphatic Filariasis. Hollis, NH: Hollis Publishing Co.
  8. Molyneux DH, Zagaria N, 2002. Lymphatic filariasis elimination: progress in global programme development. Ann Trop Med Parasitol 96 (Suppl 2): S15–S40.
  9. Vaqas B, Ryan TJ, 2003. Lymphedema: pathophysiology and management in resource-poor settings—relevance for lymphatic filariasis control programmes. Filarial J 2: 4.
  10. El Setouhy M, Ramzy RMR, Ahmed ES, Kandil AM, Hussain O, Farid HA, Helmy H, Weil GJ, 2003. A randomized clinical trial comparing single and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of Bancroftian filariasis. Am J Trop Med Hyg 70: 191–196.
  11. Dreyer G, Pires ML, Andrade LD, Lopes E, Medeiros Z, Tenorio J, Coutinho A, Noroes J, Figueredo-Silva J, 1994. Tolerance of diethylcarbamazine by microfilaraemic and amicrofilaraemic individuals in an endemic area of bancroftian filariasis, Recife, Brazil. Trans R Soc Trop Med Hyg 88: 232–236.
  12. Dreyer G, Addiss D, Noroes J, Amaral F, Rocha A, Coutinho A, 1996. Direct assessment of the adulticidal efficacy of repeat high-dose ivermectin in Bancroftian Filariasis. Trop Med Int Health 1: 427–432.
  13. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW, 2002. Mass treatment to eliminate filariasis in Papua New Guinea, N Engl J Med 347: 1841–1848.
  14. Dreyer G, Noroes J, Figueredo-Silva J, Piessens, WF, 2002. Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today 16: 544–548.
  15. Dreyer G, Medeiros Z, Netto MJ, Leal NC, de Castro LG, Piessens WF, 1999. Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg 93: 413–417.
  16. Taylor MJ, 2003. Wolbachia in the inflammatory pathogenesis of human filariasis. Ann N Y Acad Sci 990: 444–449.

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error